Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

RARE : 52.16 (+1.54%)
ABEO : 4.16 (+5.32%)
SRRK : 10.11 (+11.22%)
BNTX : 160.92 (+2.36%)
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq...

ABEO : 4.16 (+5.32%)
Philips (PHG) Expands AI Portfolio With SmartSpeed Solution

Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.

GE : 77.14 (+2.95%)
PHG : 20.12 (+0.35%)
ABEO : 4.16 (+5.32%)
ACRS : 16.90 (-4.25%)
Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant

Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.

PFE : 49.95 (+0.34%)
ABEO : 4.16 (+5.32%)
SESN : 0.7032 (-0.35%)
ROIV : 4.21 (+4.47%)
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

ALKS : 25.65 (+0.20%)
ABEO : 4.16 (+5.32%)
SESN : 0.7032 (-0.35%)
FSTX : 6.62 (+1.07%)
Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug

Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.

ALKS : 25.65 (+0.20%)
ABEO : 4.16 (+5.32%)
ACER : 1.5200 (unch)
SESN : 0.7032 (-0.35%)
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

ALKS : 25.65 (+0.20%)
ABEO : 4.16 (+5.32%)
OBSV : 0.3400 (+11.48%)
SESN : 0.7032 (-0.35%)
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.

ALKS : 25.65 (+0.20%)
CLVS : 1.5600 (+22.83%)
ABEO : 4.16 (+5.32%)
SESN : 0.7032 (-0.35%)
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy

An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.

ALKS : 25.65 (+0.20%)
BLUE : 5.93 (+7.82%)
ABEO : 4.16 (+5.32%)
SESN : 0.7032 (-0.35%)
FDA Committee Recommends bluebird's (BLUE) CALD Therapy

An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.

ALKS : 25.65 (+0.20%)
BLUE : 5.93 (+7.82%)
ABEO : 4.16 (+5.32%)
SESN : 0.7032 (-0.35%)

Barchart Exclusives

Exxon Mobil Stock Offers a Good Yield, Low P/E and Short Option Income Plays
Exxon Mobil stock is a value investor's wonder stock, offering a high yield, a low P/E multiple, and very attractive ways to make synthetic income by shorting out-of-the-money puts and calls. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar